Mainstream Surge of AI To Drug Discovery
Artificial intelligence (AI) isn’t just a buzzword anymore; it’s a revolution that’s taken the world by storm. Specifically, generative AI has become the talk of the town with the surge in ChatGPT users. But hold on, the tide seems to be turning. June 2023 marked a decline in ChatGPT traffic for the first time since its inception. But don’t be fooled, AI is far from done. It’s evolving, and one sector that’s reaping the benefits is drug discovery.
AI: The Game Changer in Drug Discovery
Finding the right targets, matching millions of combinations, and deriving treatments that can cost a fortune and take ages to hit the market – that’s the old way. Enter AI-powered drug discovery. It’s not just about saving time and money; it’s about revolutionizing the entire process from discovery to clinical trials. Predicting the safety and efficacy of new drugs even before they hit the clinical trials? That’s the power of AI.
Three AI Drug Discovery Titans You Can’t Ignore
Schrodinger Inc. (NASDAQ: SDGR)
Founded in 1990, Schrodinger isn’t just one of the oldest leading drug discovery companies; it’s a powerhouse. With its cloud-based AI and machine learning platform, it’s helping researchers predict molecular interactions like never before. Two FDA-approved drugs and a pipeline filled with oncology and immunology treatments? That’s Schrodinger for you.
Recursion Pharmaceuticals (NASDAQ: RXRX)
Recursion is making waves, and the $50 million PIPE investment from NVIDIA Co. (NASDAQ: NVDA) is just the tip of the iceberg. With its massive data universe and hundreds of billions of searchable inferences, Recursion is redefining wet lab experiments. And with recent acquisitions and collaborations, it’s beefing up its AI like no other.
Exscientia PLC (NASDAQ: EXAI)
UK-based Exscientia is more than just a drug discovery company; it’s a pioneer in personalized precision medicine. From lucrative partnerships to groundbreaking therapies for Alzheimer’s and various cancers, Exscientia is on the cutting edge of innovation.
Conclusion
AI is reshaping the world, and the drug discovery segment is a testament to its transformative power. From speeding up processes to unlocking new potentials, AI is the future, and these three companies are leading the charge.
